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The multiprotein von Hippel-Lindau (VHL) tumor
suppressor (CBCVHL, Cul2-Elongin BC-VHL) and SCF
(Skp1-Cul1/Cdc53-F-box protein) complexes are mem-
bers of structurally related families of E3 ubiquitin li-
gases that use a heterodimeric module composed of a
member of the Cullin protein family and the RING fin-
ger protein Rbx1 (ROC1/Hrt1) to activate ubiquitylation
of target proteins by the E2 ubiquitin-conjugating en-
zymes Ubc5 and Cdc34. VHL and F-box proteins function
as the substrate recruitment subunits of CBCVHL and
SCF complexes, respectively. In cells, many F-box pro-
teins are short lived and are proposed to be ubiquity-
lated by an autocatalytic mechanism and destroyed by
the proteasome following assembly into SCF complexes.
In contrast, the VHL protein is stabilized by interaction
with the Elongin B and C subunits of CBCVHL in cells. In
this report, we have presented direct biochemical evi-
dence that unlike the F-box protein Cdc4, which is ubiq-
uitylated in vitro by Cdc34 in the context of the SCF, the
VHL protein is protected from Ubc5-catalyzed ubiquity-
lation following assembly into the CBCVHL complex.
CBCVHL is continuously required for negative regula-
tion of hypoxia-inducible transcription factors in nor-
moxic cells and of SCF complexes, many of which func-
tion only transiently during the cell cycle or in response
to cellular signals. Our findings provide a molecular
basis for the different modes of cellular regulation of
VHL and F-box proteins and are consistent with the
known roles of CBCVHL.
Ubiquitylation and the subsequent proteasomal degradation
of regulatory proteins control a large number of cellular pro-
cesses, including cell cycle progression, transcription, and sig-
nal transduction. Ubiquitin-dependent protein degradation is
an elaborate, multistage process that begins with enzymatic
tagging of target proteins with a polyubiquitin chain and cul-
minates with ubiquitin-dependent degradation of tagged pro-
teins by the 26 S proteasome (1–4). In the first stage, the C
terminus of ubiquitin is covalently bound through a thioester
bond to the active site cysteine residue of an E1 ubiquitin-
activating enzyme. Ubiquitin is then transferred from the E1 to
an active site cysteine residue in one of a number of E2 ubiq-
uitin-conjugating enzymes. Finally, in a reaction mediated by
an E3 ubiquitin ligase, ubiquitin is conjugated directly via
isopeptide bonds to -amino groups of lysines in the target
protein and then to lysines in their ubiquityl moieties to com-
plete synthesis of the polyubiquitin tag.
The E3 components of the ubiquitin pathway are responsible
for recognizing and recruiting target proteins for polyubiquity-
lation. The E3 fall into two functional classes (3, 5). One class
includes the homologous to E6-AP carboxyl terminus (HECT)
domain proteins, which have an active site cysteine residue
that receives ubiquitin from an E2 ubiquitin-conjugating en-
zyme and transfers it to target proteins. The other class in-
cludes the E3 that appear to activate ubiquitylation of target
proteins at least in part by binding to both E2 ubiquitin-
conjugating enzymes and target proteins and bringing them
into close proximity. Among members of this class of E3s are
the structurally related multiprotein SCF (Skp1-Cul1/Cdc53-
F-box protein) and von Hippel-Lindau (VHL)1 tumor suppres-
sor (CBCVHL or Cul2-Elongin BC-VHL) complexes, which use
heterodimeric modules composed of a member of the Cullin
protein family and the RING finger protein Rbx1 (also referred
to as ROC1 or Hrt1) to activate ubiquitylation of target pro-
teins by the E2 ubiquitin-conjugating enzymes Cdc34 and Ubc5
(6, 7).
SCF ubiquitin ligases include a member of the F-box family
of proteins, which serve to recognize and recruit target pro-
teins. F-box proteins are linked to a Cul1(Cdc53)/Rbx1 module
by the Skp1 adaptor protein that binds to a degenerate, 40-
amino acid sequence motif called the F-box, which is present in
F-box proteins (8, 9). As a component of the CBCVHL ubiquitin
ligase, the VHL tumor suppressor protein functions analo-
gously to F-box proteins in the SCF complex to recruit target
proteins for ubiquitylation (10–14). The VHL protein is linked
to a Cul2/Rbx1 module by the ubiquitin-like Elongin B and
Skp1-like Elongin C adaptor proteins. Elongins B and C form a
stable subcomplex that binds to a short BC-box motif present in
the VHL protein (15–17).
F-box proteins, including mammalian Skp2 and Saccharo-
myces cerevisiae Cdc4, Grr1, and Met30, have recently been
shown to be short lived proteins that are rapidly turned over
with ubiquitin-dependent degradation by the proteasome when
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findings, it has been proposed that these F-box proteins are
ubiquitylated by an autocatalytic mechanism in the context of
the SCF and, further, that rapid turnover of F-box proteins
provides a mechanism for rapid assembly and disassembly of
distinct SCF complexes required for timely responses of the cell
to different cell cycle or environmental cues.
In contrast to these F-box proteins, the VHL tumor suppres-
sor protein is long lived in cells. In addition, whereas F-box
proteins are stabilized in cells by mutations that prevent them
from binding Skp1 and assembling into SCF complexes, VHL is
destabilized by mutations that interfere with its ability to bind
Elongins C and B and assemble into CBCVHL (22). Notably, the
hypoxia-inducible transcription factors HIF1 and HIF2 were
recently shown to be targets of the CBCVHL ubiquitin ligase
(10–14). HIF1 and HIF2 are continuously synthesized in
cells grown under normoxic conditions but are rapidly ubiqui-
tylated by the CBCVHL complex and degraded by the protea-
some. Under hypoxic conditions (23–25) or in cells lacking a
functional VHL gene (10, 26–28), HIF1 and HIF2 are stabi-
lized and accumulate and activate expression of their target
genes. Based on these findings, the longevity of the VHL pro-
tein in cells is likely to ensure that it can maintain close and
continuous surveillance of hypoxia-inducible transcription fac-
tors, which may be activated at any time during the life of a
cell.
In this report, we have investigated the molecular basis of
the different modes of regulation of VHL and F-box proteins.
We have demonstrated that unlike the F-box protein Cdc4,
which is ubiquitylated in vitro by Cdc34 in the context of the
SCF, the VHL protein is protected from Ubc5-catalyzed ubiq-
uitylation in the context of CBCVHL even though the RING
finger protein Rbx1 is capable of directly targeting VHL for
ubiquitylation when it is not assembled into the CBCVHL com-
plex. Our findings provide a plausible model to explain the
differential stabilities of VHL and F-box proteins, and they
suggest that the longevity of the VHL tumor suppressor protein
is regulated at least in part by the geometry of the CBCVHL
complex through the spatial organization of its surface lysine
residues.
EXPERIMENTAL PROCEDURES
Materials—Anti-VHL monoclonal antibody (Ig32) was purchased
from BD PharMingen. Anti-Cul2 and anti-Elongin C monoclonal anti-
bodies were obtained from Transduction Laboratories. Anti-Myc mono-
clonal antibody (9E10) was from Roche Molecular Biochemicals. Anti-
protein C monoclonal antibody (HPC4) was a generous gift from C. T.
Esmon (Oklahoma Medical Research Foundation). Anti-T7 monoclonal
antibody was purchased from Invitrogen. Anti-HSV monoclonal anti-
body was obtained from Novagen. Anti-Elongin B rabbit polyclonal
antibody has been described (29).
Expression of Recombinant Proteins in Escherichia coli—Human
Ubc5a, human Ubc3 containing an N-terminal His6 tag, S. cerevisiae
Uba1 containing an N-terminal Myc tag and a C-terminal His6, S.
cerevisiae Cdc34 containing an N-terminal His6, and mouse ubiquitin-
K48R containing an N-terminal GST tag (GSTUbK48R) were described
previously (13, 30, 31). Proteins were expressed in E. coli strain BL21
(DE3) and purified by Ni2-agarose or glutathione-Sepharose affinity
chromatography. After dialysis against 40 mM Hepes-NaOH (pH 7.9),
60 mM potassium acetate, 2 mM DTT, 1 mM MgCl2, 0.5 mM EDTA (pH
7.9), and 10% (v/v) glycerol, proteins were stored at 80 °C.
Expression of Recombinant Proteins in Sf21 Insect Cells—Wild type
human VHL and VHL mutants [K159R/K167R/K196R]VHL,
[L158P]VHL, and [C162F]VHL; wild type human VHL and VHL mu-
tant [L158P]VHL containing an N-terminal His6 tag (HisVHL
WT and
HisVHLL158P); human Cul2; human Elongin B; human Elongin B con-
taining an N-terminal His6 tag and a C-terminal HPC4 tag
(HisHPC4EloB); mouse wild type Rbx1 and Rbx1 mutant [C94S]Rbx1
containing an N-terminal Myc tag (MycRbx1WT and MycRbx1C94S); S.
cerevisiae Rbx1 containing N-terminal His6 and Myc tags (His-
MycscRbx1); S. cerevisiae Cdc4 containing N-terminal His6 and HSV
tags (His-HSVCdc4); Cdc4VHL chimeric protein containing N-terminal
His6 and FLAG tags; and human Elongin C were subcloned into
pBacPAK8. Recombinant baculoviruses were generated with the
BacPAK baculovirus expression system (CLONTECH). The baculovi-
ruses encoding mouse Rbx1 containing N-terminal His6 and Myc tags,
(His-MycRbx1) (32), S. cerevisiae Cdc53 (33), and S. cerevisiae Skp1
containing three N-terminal FLAG tags (FLAG-Skp1) (34), have been
described previously. Sf21 cells were cultured in Sf-900 II serum-free
medium with 5% fetal calf serum, penicillin (100 units/ml), and strep-
tomycin (100 g/ml) at 27 °C. Sf21 cells were coinfected with the re-
combinant baculoviruses indicated in the figures. Sixty hours after
infection, cells were collected and lysed in ice-cold buffer containing 40
mM Hepes-NaOH (pH 7.9), 150 mM NaCl, 1 mM DTT, 0.5% (v/v) Triton
X-100, 10% (v/v) glycerol, 5 g/ml leupeptin, 5 g/ml antipain, 5 g/ml
pepstatin A, and 5 g/ml aprotinin. In some experiments, cells were
resuspended in ice-cold buffer containing 40 mM Hepes-NaOH (pH 7.9),
150 mM NaCl, 20 mM imidazole (pH 7.9), 5 g/ml leupeptin, 5 g/ml
antipain, 5 g/ml pepstatin A, and 5 g/ml aprotinin and lysed by
French press (1 inch piston, 16,000 psi cell pressure; American Instru-
ment Company).
Purification of Recombinant CBC and SCF Complexes from Sf21 Cell
Lysates—Sf21 cells were coinfected with the baculoviruses indicated in
the figure legends. Cells were harvested and lysed using a French press
as described above. Following centrifugation at 10,000 g for 20 min at
4 °C, the resulting supernatant was mixed with 1 ml of Ni2-agarose
pre-equilibrated in buffer containing 40 mM Hepes-NaOH (pH 7.9), 150
mM NaCl, and 20 mM imidazole (pH 7.9). After 2 h, the Ni2-agarose
was washed three times with the same buffer and packed into a 0.8-cm
diameter column. The column was eluted stepwise with buffer contain-
ing 40 mM Hepes-NaOH (pH 7.9), 50 mM NaCl, 300 mM imidazole (pH
7.9), and 10% (v/v) glycerol. Peak fractions containing the recombinant
proteins were diluted with 40 mM Tris-HCl (pH 7.9), 10% (v/v) glycerol,
1 mM DTT, and 0.5 mM EDTA and brought to a conductivity equivalent
to that of the same buffer containing 40 mM KCl. Following centrifuga-
tion at 10,000  g for 20 min at 4 °C, the resulting supernatant was
applied to a TSK DEAE-NPR HPLC column (4.6  35 mM; Toso-Haas)
pre-equilibrated in buffer containing 40 mM Tris-HCl (pH 7.9), 40 mM
KCl, 10% (v/v) glycerol, 1 mM DTT, and 0.5 mM EDTA. The column was
eluted at 0.2 ml/min with a 5-ml linear gradient from 40 to 550 mM KCl,
and 0.2-ml fractions were collected.
Immunoprecipitations and Western Blotting—Sf21 and 293T cells
were harvested and lysed as described above. Cell lysates were incu-
bated for 2 h at 4 °C with protein A-Sepharose and the antibodies
indicated in the figure legends. Protein A-Sepharose was washed three
times in buffer containing 40 mM Hepes-NaOH (pH 7.9), 150 mM NaCl,
1 mM DTT, 0.5 mM EDTA (pH 7.9), and 0.5% (v/v) Triton X-100.
Immunoprecipitated proteins were separated by SDS-polyacrylamide
gel electrophoresis, transferred to Hybond P membranes (Amersham
Biosciences), and visualized by Western blotting with Supersignal West
Pico chemiluminescent reagent (Pierce).
In Vitro Ubiquitylation Assay—To assay immunoprecipitated
CBCVHL and SCFCdc4 complexes for their abilities to ubiquitylate the
VHL protein, Sf21 cells coinfected with the baculoviruses indicated in
the figures were lysed with ice-cold buffer containing 40 mM Hepes-
NaOH (pH 7.9), 150 mM NaCl, 1 mM DTT, 0.5% (v/v) Triton X-100, 10%
(v/v) glycerol, 5 g/ml leupeptin, 5 g/ml antipain, 5 g/ml pepstatin A,
and 5 g/ml aprotinin. After centrifugation at 10,000  g for 20 min at
4 °C, the supernatants were immunoprecipitated with 2 g of anti-VHL
(Ig32), anti-FLAG, or anti-HPC4 antibodies and 10 l of protein A-
Sepharose. The beads were mixed with 50 ng of Uba1, 3 g of
GSTUbK48R, and either 100 ng of hUbc5a or 200 ng of ScCdc34 in a
20-l reaction containing 40 mM Hepes-NaOH (pH 7.9), 60 mM potas-
sium acetate, 2 mM DTT, 5 mM MgCl2, 0.5 mM EDTA (pH 7.9), 10% (v/v)
glycerol, and 1.5 mM ATP. Reaction mixtures were incubated for 1 h at
26 °C.
To assay the abilities of purified recombinant CBC and SCF com-
plexes to ubiquitylate VHL, Cdc4VHL, and Cdc4 proteins, aliquots of
TSK DEAE-NPR HPLC column fractions indicated in the figures were
mixed with 50 ng of Uba1, 3 g of GSTUbK48R, and either 100 ng
of hUbc5a or 200 ng of ScCdc34 in a 10-l reaction containing 40 mM
Hepes-NaOH (pH 7.9), 60 mM potassium acetate, 2 mM DTT, 5 mM
MgCl2, 0.5 mM EDTA (pH 7.9), 10% (v/v) glycerol, and 1.5 mM ATP.
Reaction mixtures were incubated for 1 h at 26 °C.
RESULTS AND DISCUSSION
The VHL Protein Is Protected from Ubiquitylation in the
Context of the CBCVHL Complex—The observation that VHL is
more stable in cells when it is associated with Elongins B and
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C (22) raised the possibility that the VHL protein might be
protected from ubiquitylation and subsequent degradation by
assembly into the CBCVHL complex. To address this possibility
directly, Sf21 insect cells were coinfected with various combina-
tions of baculoviruses encoding Cul2, Rbx1, Elongins B and C, and
either wild type VHL, VHL mutant [K159R,K171R,K196R]VHL,
which has no lysines and therefore cannot be ubiquitylated, or VHL
mutants [L158P]VHL and [C162F]VHL, which exhibit substan-
tially reduced affinities for Elongins B and C. We note that al-
though Elongin C is capable of interacting with VHL in the absence
of Elongin B, Elongins B and C were always coexpressed together
in these experiments for the following reasons. (i) The binding of
Elongin C to VHL is stabilized by Elongin B both in vitro and in
cells (16, 35). (ii) Elongin C is stabilized and expressed to consider-
ably higher levels in insect cells that also express Elongin B (data
not shown). (iii) The detectable Elongin C is always found in asso-
ciation with Elongin B during biochemical purification of Elongin
C-containing complexes (Ref. 36 and data not shown).
VHL-containing complexes were immunoprecipitated with
an anti-VHL monoclonal antibody and tested for their suscep-
tibility to VHL ubiquitylation. In these experiments, immuno-
purified complexes (Fig. 1A, lanes 1–9) were incubated with an
E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating
enzyme Ubc5a, ubiquitin (GSTUbK48R), and ATP. Reaction
products were analzyed by Western blotting with anti-VHL
antibody. As shown in Fig. 1B, maximal formation of the more
slowly migrating VHL-GSTUbK48R conjugates was observed in
reactions performed with VHL complexes immunoprecipitated
from insect cells expressing wild type VHL, Cul2, and Rbx1
(lane 2). Formation of these more slowly migrating species was
strongly inhibited by the presence of Elongins B and C (lanes 3
and 7) and was not observed in VHL immunoprecipitates from
insect cells expressing the [K159R,K171R,K196R]VHL mutant
(lanes 4 and 5). Further supporting the notion that binding of
Elongins B and C to VHL blocks its ubiquitylation, VHL mu-
tants [L158P]VHL and [C162F]VHL are more efficiently ubiq-
uitylated than wild type VHL, even when present in VHL
immunoprecipitates from cells expressing high levels of Elon-
gins B and C (lanes 8 and 9). To confirm and extend these
findings, wild type VHL, Cul2, Rbx1, Elongin C, and an
epitope-tagged Elongin B (HPC4EloB) were coexpressed in
insect cells and coimmunopurified with anti-HPC4 monoclonal
antibodies. This procedure ensured that all of the immunopre-
cipitated VHL protein was associated with Elongins B and C.
As shown in Fig. 1A, lanes 10 and 11, anti-HPC4 immunopre-
cipitates contained all five subunits of the CBCVHL complex.
Notably, the VHL protein contained in these Elongin B-con-
taining complexes was resistant to ubiquitylation (Fig. 1B,
lanes 10 and 11).
Rbx1 Directs Ubiquitylation of VHL in the Absence of Elon-
gins B and C—The results of the experiments described above
argue that VHL ubiquitylation can be negatively regulated by
its binding to Elongins B and C and/or by its assembly into
complete CBCVHL complexes containing Cul2, Elongins B and
C, and Rbx1. However, they provide no information about
the mechanism of VHL ubiquitylation outside the context of
CBCVHL. In the course of investigating interactions among
subunits of the CBCVHL complex, we have observed that Rbx1
binds to VHL in the absence of exogenously expressed Cul2 and
Elongins B and C (32), raising the possibility that Rbx1 might
be capable of directly activating VHL ubiquitylation. To ad-
dress this possibility, His6-tagged wild type VHL or His6-
tagged [L158P]VHL were expressed in Sf21 insect cells alone,
with Rbx1, or in combination with Rbx1, Cul2, and Elongins B
and C. VHL or VHL-containing complexes were purified from
cell lysates by consecutive Ni2-agarose chromatography and
TSK DEAE-NPR HPLC. As shown in the Coomassie Blue-
stained SDS-polyacrylamide gel in Fig. 2A, wild type VHL
could be purified as an approximately stoichiometric compo-
nent of the complete CBCVHL complex. In addition, both wild
type VHL and the [L158P]VHL mutant could be purified with
approximately stoichiometric amounts of Rbx1 in the absence
of exogenously expressed Cul2 and Elongins B and C.
Purified VHL and VHL-containing complexes were incu-
bated with E1 ubiquitin-activating enzyme, the E2 ubiquitin-
conjugating enzyme Ubc5a, GSTUbK48R, and ATP. Consistent
with the results in Fig. 1, we observed no detectable ubiquity-
lation of VHL in the context of the purified CBCVHL complex.
Purified VHL and [L158P]VHL formed VHL-UbK48R conju-
gates with electrophoretic mobilities corresponding to those
expected for addition of a single GSTUbK48R. In contrast, high
molecular mass VHL-GSTUbK48R conjugates were formed
when VHL and [L158P]VHL were present as components of
VHLRbx1 complexes (Fig. 2, B and C).
To investigate further the requirement for Rbx1 in the for-
mation of high molecular mass VHL-GSTUbK48R conjugates,
we compared VHL ubiquitylation in the presence of wild type
Rbx1 and the Rbx1 mutant [C94S], which does not support
activation of either Cdc34-dependent ubiquitylation of Cln2 by
FIG. 1. The VHL protein is protected from ubiquitylation in
the context of the CBCVHL complex. A, Sf21 cells were infected with
baculoviruses encoding the indicated proteins. Anti-VHL (Ig32, lanes
1–9) or anti-HPC4 (lanes 10 and 11) immunoprecipitates were subjected
to 8 or 13% SDS-PAGE followed by Western blotting as described under
“Experimental Procedures.” The antibodies used to probe immunoblots
are indicated to the left of the gel images. B, complexes immunoprecipi-
tated with anti-VHL (Ig32, lanes 1–9) or antibodies against the HPC4
epitope tag on Elongin B (lanes 10 and 11) were assayed for their
abilities to activate VHL ubiquitylation as described under “Experimen-
tal Procedures” (lower panels). HC, immunoglobulin heavy chain; IP,
immunoprecipitate; WB, Western blot; Ub assay, ubiquitylation assay.
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SCFGrr1 complexes or Ubc12-dependent Rub1 modification of
Cullin proteins (31). In these experiments, His6-tagged VHL
was coexpressed in insect cells with either Rbx1 or [C94S]Rbx1.
The resulting complexes were purified from cell lysates by
consecutive Ni2-agarose chromatography and TSK DEAE-
NPR HPLC. As shown in Fig. 3A, approximately stoichiometric
amounts of both wild type and mutant Rbx1 copurified with the
VHL protein. In addition, high molecular mass VHL-
GSTUbK48R conjugates were formed only in the presence of
wild type Rbx1 (Fig. 3, B and C), indicating that VHL ubiqui-
tylation depends on the presence of functional Rbx1.
The F-box Protein Cdc4 Can Be Ubiquitylated in the Context
of the SCFCdc4 Complex—The S. cerevisiae F-box protein Cdc4
is rapidly ubiquitylated and degraded by the proteasome in
cells (18, 19). Based on the observations that (i) Cdc4 turnover
depends upon its ability to interact with the SCF components
Skp1 and Cdc53, and (ii) Cdc4 is stabilized when cells contain-
ing a temperature-sensitive Skp1 mutant are grown at the
non-permissive temperature, it has been proposed that Cdc4
can be ubiquitylated in the context of an SCFCdc4 complex (18,
19). However, direct evidence in support of this model has not
been reported. To test this possibility, we asked whether a
recombinant SCFCdc4 complex, expressed in and purified from
Sf21 insect cells, is capable of promoting Cdc4 ubiquitylation.
N-terminal His6- and HSV-tagged Cdc4 (His-HSVCdc4), S.
cerevisiae Cdc53, N-terminal FLAG-tagged S. cerevisiae Skp1
(FLAG-Skp1), and N-terminal His6- and Myc-tagged S. cerevi-
siae Rbx1 (His-MycScRbx1) were coexpressed in Sf21 insect
cells and purified from cell lysates by consecutive Ni2-agarose
chromatography and TSK DEAE-NPR HPLC. The purified
SCFCdc4 complexes are shown in Fig. 4A, left panel. As shown
in Fig. 4A, right panel, high molecular mass Cdc4-GSTUbK48R
conjugates appeared in a time-dependent manner following
incubation of the purified SCFCdc4 complexes with E1 ubiq-
uitin-activating enzyme, E2 ubiquitin-conjugating enzyme
Cdc34, GSTUbK48R, and ATP.
Although these results strongly suggested that Cdc4 can be
ubiquitylated in the context of the SCFCdc4 complex, it was
possible that the ubiquitylated Cdc4 in these reactions was not
actually a component of SCF complexes but rather represented
contaminating free Cdc4 in the purified SCFCdc4 fraction. To
prepare SCFCdc4 complexes free of contaminating Cdc4, SCF
subunits were coexpressed in insect cells and immunoprecipi-
tated from cell lysates with antibodies recognizing the FLAG
epitope on Skp1 (Fig. 4B, left panel). Immunoprecipitated com-
plexes were then incubated with E1 ubiquitin-activating en-
zyme, E2 ubiquitin-conjugating enzyme Cdc34, GSTUbK48R,
FIG. 2. Rbx1-dependent ubiquitylation of chromatographi-
cally purified VHL. A, the indicated recombinant proteins were ex-
pressed in Sf21 cells and purified by Ni2-agarose and TSK-DEAE
HPLC as described under “Experimental Procedures.” Purified VHL
and VHL-containing complexes were subjected to 13% SDS-PAGE, and
proteins were visualized by Coomassie Blue staining. B, the purified
VHL and VHL-containing complexes shown in panel A were subjected
to 13% SDS-PAGE and analyzed by Western blotting using the Ig32
anti-VHL monoclonal antibody. C, purified VHL and VHL-containing
complexes shown in panel A were assayed as described under “Exper-
imental Procedures” for their abilities to activate VHL ubiquitylation in
the presence of100 ng of hUbc5a. Reaction products were subjected to
13% SDS-PAGE and analyzed by Western blotting using Ig32. The
asterisk indicates the position of an unknown polypeptide recognized by
Ig32.
FIG. 3. An Rbx1 RING finger mutant is impaired in its ability
to support VHL ubiquitylation. A, the indicated recombinant pro-
teins were expressed in Sf21 cells and purified by Ni2-agarose and
TSK-DEAE HPLC as described under “Experimental Procedures.” Pu-
rified VHLRbx1 complexes were subjected to 13% SDS-PAGE, and pro-
teins were visualized by Coomassie Blue staining. B, the purified
VHLRbx1 complexes shown in panel A were subjected to 13% SDS-PAGE
and analyzed by Western blotting using the Ig32 anti-VHL monoclonal
antibody. C, purified VHLRbx1 complexes shown in panel A were as-
sayed as described under “Experimental Procedures” for their abilities
to activate VHL ubiquitylation in the presence of 100 ng of hUbc5a.
Reaction products were subjected to 13% SDS-PAGE and analyzed by
Western blotting using Ig32. The asterisk indicates the position of an
unknown polypeptide recognized by Ig32.
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and ATP. As shown in Fig. 4B (right panel), similar to the
results obtained with chromatographically purified SCFCdc4
complexes, high molecular mass Cdc4-GSTUbK48R conjugates
were also formed in the presence of immunoprecipitated com-
plexes. Thus, unlike the VHL protein in the CBCVHL complex,
the Cdc4 protein can be ubiquitylated in the context of the
SCFCdc4 complex.
To account for the observation that Cdc4, a target recruit-
ment subunit of the SCF complex, can be ubiquitylated in the
context of SCFCdc4 (whereas VHL, a CBC target recruitment
subunit, is protected from ubiquitylation in the context of
CBCVHL), we considered the possibility that CBC complexes
might be inherently incapable of supporting ubiquitylation of
associated target recruitment subunits. To address this hy-
pothesis, we constructed an N-terminal His6-tagged Cdc4
VHL
chimera that contained the entire VHL open reading frame,
including the BC-box and the Cdc4 WD-40 repeat domain but
lacked the Cdc4 F-box (Fig. 5A). The Cdc4VHL chimera was
coexpressed in Sf21 insect cells with Cul2, Rbx1, and Elongins
B and C; the resulting CBC-Cdc4VHL complex was purified
from cell lysates by consecutive Ni2-agarose chromatography
and TSK DEAE-NPR HPLC. The purified CBC-Cdc4VHL com-
plex is shown in Fig. 5B. As shown in Fig. 5C, high molecular
mass Cdc4VHL-UbK48R conjugates were formed in a time-de-
pendent manner following incubation of the purified CBC-
Cdc4VHL complex with E1 ubiquitin-activating enzyme, E2
ubiquitin-conjugating enzyme Ubc5a, GSTUbK48R, and ATP,
indicating that the Cdc4VHL chimera can be ubiquitylated in
the context of the CBC-Cdc4VHL complex. Thus, the resistance
of VHL to ubiquitylation in the context of the CBCVHL complex
does not reflect an inherent inability of CBC complexes to
ubiquitylate their target recruitment subunits, and therefore
resistance to ubiquitylation must be a property of the VHL
protein itself.
Summary and Perspective—In this report we have investi-
gated the molecular basis of the different modes of regulation of
the VHL tumor suppressor protein as the target recruitment
subunit of the CBCVHL ubiquitin ligase and of F-box proteins as
target recruitment subunits of the structurally related SCF
ubiquitin ligases. Our findings provide a plausible model to
explain the different stabilities of the VHL and of F-box pro-
teins in cells. Unlike the F-box proteins Cdc4, Grr1, and Met30,
which can be ubiquitylated in the context of the SCF and
degraded by the proteasome, the VHL protein is resistant to
ubiquitylation in the context of the CBCVHL complex, thus
accounting at least in part for its long half-life in cells and
consistent with its continuous requirement in negative regula-
tion of the levels of hypoxia-inducible transcription factors
throughout all phases of the cell cycle. Our observation that the
Cdc4VHL chimera can be ubiquitylated in the context of the
CBC-Cdc4VHL complex suggests that the resistance of VHL to
ubiquitylation in the CBCVHL complex is not an intrinsic prop-
erty of the CBC complex conferred by one or more of its Cul2,
Rbx1, and Elongin B and C subunits but instead is a property
of the VHL protein regulated by the geometry of the CBCVHL
complex. The human VHL protein contains three lysine resi-
dues that are found in its C-terminal -domain (37) at positions
159, 171, and 196 and that are potential ubiquitylation sites.
The lysine at position 159, which is located within the Elongin
FIG. 4. The F-box protein Cdc4 can be ubiquitylated in vitro in
the context of the SCFCdc4 complex. A, the indicated recombinant
proteins were expressed in Sf21 cells and purified by Ni2-agarose and
TSK-DEAE HPLC as described under “Experimental Procedures.” Pu-
rified SCFCdc4 complexes were subjected to 13% SDS-PAGE, and pro-
teins were visualized by Coomassie Blue staining (left panel). The
purified complexes were assayed as described under “Experimental
Procedures” for the ability to activate Cdc4 ubiquitylation activity in
the presence of 200 ng of scCdc34. Reaction mixtures were incubated
for the times indicated. Reaction products were subjected to 8% SDS-
PAGE, and proteins were visualized by Western blotting using anti-
HSV antibody (right panel). B, total cell lysates and anti-FLAG immu-
noprecipitates from lysates of Sf21 cells infected with indicated
baculoviruses were subjected to 8 or 13% SDS-PAGE. Proteins were
visualized by Western blotting using antibodies directed against the
proteins indicated in the left panel. The immunoprecipitates were as-
sayed as described under “Experimental Procedures” for their abilities
to activate Cdc4 ubiquitylation in the presence of  200 ng of scCdc34.
Reaction mixtures were incubated for the times indicated. Reaction
products were subjected to 8% SDS-PAGE, and proteins were visualized
by Western blotting using anti-HSV antibody.
FIG. 5. A Cdc4VHL chimera is ubiquitylated in the context of
CBC-Cdc4VHL. A, the Cdc4VHL chimera contains residues 341–779 of
Cdc4 fused to the complete VHL open reading frame. The Cdc4 F-box is
indicated by the black box, and the VHL BC-box is indicated by the
hatched box. B, the indicated recombinant proteins were expressed in
Sf21 cells and purified as described under “Experimental Procedures.”
CBC complexes were subjected to 13% SDS-PAGE, and proteins were
visualized by Coomassie Blue staining. C, CBC-Cdc4VHL (lanes 1–3) or
CBCVHL (lanes 4 and 5) complexes were assayed for their abilities to
activate ubiquitylation of Cdc4VHL or VHL in the presence of100 ng of
hUbc5a. Reaction mixtures were incubated for the indicated times.
Reaction products were subjected to 11% SDS-PAGE, and proteins were
visualized by Western blotting with the Ig32 anti-VHL monoclonal
antibody.
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BC binding site and is hydrogen-bonded to Asn-108 of Elongin
C, would be predicted to be protected from ubiquitylation by
interaction of VHL with Elongins B and C. The lysines at
positions 171 and 196 lie on exposed surfaces of VHL within the
VHL-Elongin BC complex. Whether Cul2 and Rbx1 physically
block access of the E2 to Lys-171 and -196 or whether some
other aspect(s) of the geometry of the complex prevents their
ubiquitylation awaits structural studies of the intact CBCVHL
complex. Interestingly, in recent experiments we have ob-
served that, although the E2 ubiquitin-conjugating enzymes
Ubc5 and Cdc34 can both be activated to synthesize polyubiq-
uitin chains conjugated to Cul2 in the context of the CBC
complex, the two enzymes transfer ubiquityl moieties to lysines
at different sites on Cul2.2 Thus, the overall geometry of lysines
on the surface of target proteins is likely to contribute to
regulation of their ubiquitylation by CBC and SCF ubiquitin
ligases. Experiments are underway to decipher the rules gov-
erning the choice of surface lysines by different E2 enzymes
and should shed light on this mode of regulation.
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